Sponsors (7)
Introduced March 16, 2026 by James Baird · Last progress March 16, 2026
The bill aims to accelerate commercialization, workforce development, and domestic bioindustrial capacity by funding shared maturation facilities and open access, but it requires taxpayer funding, risks reducing private investment incentives and IP-related recruitment, and may concentrate benefits among established institutions while de-emphasizing basic research.
Researchers, biotech startups, tech workers, and small businesses gain routine access to shared, state-of-the-art precommercial/maturation facilities to validate and scale processes, accelerating commercialization and helping attract private investment.
State governments, small businesses, and the broader public benefit from strengthened domestic bioindustrial manufacturing capacity and supply-chain resilience through geographically sited facilities and Federal coordination.
Students and regional workforces receive training and workforce-development opportunities tied to facility activities, supporting job creation and regional employment pipelines.
Taxpayers face increased federal spending (authorization and likely subsidies) totaling the $225.5M authorization and additional build/operational costs, which could divert funds from other priorities.
Small businesses and private investors may be less willing to invest or partner if open-access requirements and public-domain IP limit proprietary protection and commercial returns.
Federal employees and prospective recruits could be discouraged because work-created IP is declared public domain, reducing personal or institutional incentives tied to IP ownership.
Based on analysis of 3 sections of legislative text.
Requires the Department to establish at least two open-access bioindustrial technology maturation facilities by Sept 30, 2030 and adds related definitions to support scale-up.
Requires the Department to establish at least two precommercial bioindustrial "technology maturation" facilities—user facilities that provide prototyping, pilot-scale testing, demonstration, and early-stage manufacturing services—to de-risk biotechnology products and processes and strengthen domestic biomanufacturing capacity. It adds statutory definitions (including biomanufacturing, biointermediate, open access, phytobiome, and technology maturation) and directs the Secretary to site facilities with geographic diversity and complementarity to existing capabilities, with an overall deadline of September 30, 2030. The law sets planning and siting criteria (industry needs, infrastructure gaps, fermentation capacity, workforce alignment, and regional inputs) and requires that facilities provide open-access infrastructure and services, but it does not appropriate funding or create explicit funding authorizations in the text provided.